Literature DB >> 1464371

Endowing T cells with antibody specificity using chimeric T cell receptors.

G Gross1, Z Eshhar.   

Abstract

T cells recognize antigen in the form of a peptide associated with a cell surface molecule encoded by the major histocompatibility gene complex (MHC). The elaborate requirements for the T cell receptor (TCR)-antigen interaction stand in contrast to the simple and defined nature of the antigenic determinants recognized by antibodies. The similarity in the molecular structure and gene organization between antibodies and the TCR has prompted attempts to interchange the antigen-binding, variable regions of these molecules. To this end, chimeric TCR (cTCR) genes, composed of the variable domains of antibodies linked to TCR constant regions, have been used to confer antibody-type specificity on T cells. cTCR-expressing T cells respond to stimulator cells as well as to immobilized antigen in an MHC unrestricted and independent manner. The antibody-like specificity of the resulting T cells has been exploited, using defined ligands, to elucidate the physicochemical parameters that govern TCR-mediated signaling, and to provide a useful experimental system to study the role of MHC and cell-adhesion/accessory molecules in T cell activation. The successful expression of such cTCR in transgenic mice opens new avenues to explore the role of the MHC in T cell development and maturation. Eventually, chimeric receptors specific to tumor or viral antigens might be used for in vivo targeting of T cells in the framework of immuno- and gene therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1464371     DOI: 10.1096/fasebj.6.15.1464371

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  18 in total

Review 1.  Immunotherapy for primary brain tumors: no longer a matter of privilege.

Authors:  Peter E Fecci; Amy B Heimberger; John H Sampson
Journal:  Clin Cancer Res       Date:  2014-11-15       Impact factor: 12.531

Review 2.  Recombinant antibodies for the diagnosis and treatment of cancer.

Authors:  Jürgen Krauss
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

Review 3.  Vectors for cancer gene therapy.

Authors:  J Zhang; S J Russell
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

Review 4.  The T-body approach: potential for cancer immunotherapy.

Authors:  Z Eshhar; N Bach; C J Fitzer-Attas; G Gross; J Lustgarten; T Waks; D G Schindler
Journal:  Springer Semin Immunopathol       Date:  1996

Review 5.  Targeting of peripheral blood T lymphocytes.

Authors:  R L Bolhuis; H R Hoogenboom; J W Gratama
Journal:  Springer Semin Immunopathol       Date:  1996

6.  From the mouse cage to human therapy: a personal perspective of the emergence of T-bodies/chimeric antigen receptor T cells.

Authors:  Zelig Eshhar
Journal:  Hum Gene Ther       Date:  2014-09       Impact factor: 5.695

7.  Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma.

Authors:  Edward A Stadtmauer; Thomas H Faitg; Daniel E Lowther; Ashraf Z Badros; Karen Chagin; Karen Dengel; Malini Iyengar; Luca Melchiori; Jean-Marc Navenot; Elliot Norry; Trupti Trivedi; Ruoxi Wang; Gwendolyn K Binder; Rafael Amado; Aaron P Rapoport
Journal:  Blood Adv       Date:  2019-07-09

8.  Functional expression in mast cells of chimeric receptors with antibody specificity.

Authors:  N L Bach; T Waks; D G Schindler; Z Eshhar
Journal:  Cell Biophys       Date:  1994

9.  Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells.

Authors:  D Moritz; W Wels; J Mattern; B Groner
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

10.  Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells.

Authors:  Michael Schmueck-Henneresse; Bilal Omer; Thomas Shum; Haruko Tashiro; Maksim Mamonkin; Natalia Lapteva; Sandhya Sharma; Lisa Rollins; Gianpietro Dotti; Petra Reinke; Hans-Dieter Volk; Cliona M Rooney
Journal:  J Immunol       Date:  2017-05-26       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.